Kidney cancer -- also called renal cancer -- is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Almost all kidney cancers first appear in the lining of tiny tubes (tubules) in the kidney. This type of kidney cancer is called renal cell carcinoma.
Renal cell carcinoma (RCC) is a common malignant tumor worldwide, referred to as kidney cancer. According to the World Health Organization, the global incidence of kidney cancer accounts for 2% to 3% of systemic tumors. Among malignant tumors of the urinary system, its incidence is second only to bladder cancer, and it is increasing year by year. In recent years, targeted therapy and precision therapy have become standard treatments for kidney cancer.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Medicine. This report contains market size and forecasts of Kidney Cancer Medicine in global, including the following market information:
Global Kidney Cancer Medicine Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global Kidney Cancer Medicine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Monoclonal Antibody Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Kidney Cancer Medicine include Pfizer, Bristol-Myers Squibb, Roche, GSK, Novartis, Bayer, Merck & Co., Exelixis and Takeda, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Kidney Cancer Medicine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Kidney Cancer Medicine Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Kidney Cancer Medicine Market Segment Percentages, by Type, 2022 (%)
Monoclonal Antibody
mTOR Inhibitors
Kinase Inhibitors
Other
Global Kidney Cancer Medicine Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Kidney Cancer Medicine Market Segment Percentages, by Application, 2022 (%)
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
Global Kidney Cancer Medicine Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Kidney Cancer Medicine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Kidney Cancer Medicine revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Kidney Cancer Medicine revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Bristol-Myers Squibb
Roche
GSK
Novartis
Bayer
Merck & Co.
Exelixis
Takeda
Eisai
CTTQ
AVEO Oncology
Everest Pharm
Cipla
NATCO
Beacon Pharma
SAMARTH
Outline of Major Chapters:
Chapter 1: Introduces the definition of Kidney Cancer Medicine, market overview.
Chapter 2: Global Kidney Cancer Medicine market size in revenue.
Chapter 3: Detailed analysis of Kidney Cancer Medicine company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Kidney Cancer Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Kidney Cancer Medicine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Kidney Cancer Medicine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Kidney Cancer Medicine Overall Market Size
2.1 Global Kidney Cancer Medicine Market Size: 2022 VS 2032
2.2 Global Kidney Cancer Medicine Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Kidney Cancer Medicine Players in Global Market
3.2 Top Global Kidney Cancer Medicine Companies Ranked by Revenue
3.3 Global Kidney Cancer Medicine Revenue by Companies
3.4 Top 3 and Top 5 Kidney Cancer Medicine Companies in Global Market, by Revenue in 2022
3.5 Global Companies Kidney Cancer Medicine Product Type
3.6 Tier 1, Tier 2 and Tier 3 Kidney Cancer Medicine Players in Global Market
3.6.1 List of Global Tier 1 Kidney Cancer Medicine Companies
3.6.2 List of Global Tier 2 and Tier 3 Kidney Cancer Medicine Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Kidney Cancer Medicine Market Size Markets, 2022 & 2032
4.1.2 Monoclonal Antibody
4.1.3 mTOR Inhibitors
4.1.4 Kinase Inhibitors
4.1.5 Other
4.2 By Type - Global Kidney Cancer Medicine Revenue & Forecasts
4.2.1 By Type - Global Kidney Cancer Medicine Revenue, 2018-2023
4.2.2 By Type - Global Kidney Cancer Medicine Revenue, 2024-2032
4.2.3 By Type - Global Kidney Cancer Medicine Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Kidney Cancer Medicine Market Size, 2022 & 2032
5.1.2 Renal Cell Carcinoma (RCC)
5.1.3 Transitional Cell Carcinoma (TCC)
5.2 By Application - Global Kidney Cancer Medicine Revenue & Forecasts
5.2.1 By Application - Global Kidney Cancer Medicine Revenue, 2018-2023
5.2.2 By Application - Global Kidney Cancer Medicine Revenue, 2024-2032
5.2.3 By Application - Global Kidney Cancer Medicine Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Kidney Cancer Medicine Market Size, 2022 & 2032
6.2 By Region - Global Kidney Cancer Medicine Revenue & Forecasts
6.2.1 By Region - Global Kidney Cancer Medicine Revenue, 2018-2023
6.2.2 By Region - Global Kidney Cancer Medicine Revenue, 2024-2032
6.2.3 By Region - Global Kidney Cancer Medicine Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Kidney Cancer Medicine Revenue, 2018-2032
6.3.2 US Kidney Cancer Medicine Market Size, 2018-2032
6.3.3 Canada Kidney Cancer Medicine Market Size, 2018-2032
6.3.4 Mexico Kidney Cancer Medicine Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Kidney Cancer Medicine Revenue, 2018-2032
6.4.2 Germany Kidney Cancer Medicine Market Size, 2018-2032
6.4.3 France Kidney Cancer Medicine Market Size, 2018-2032
6.4.4 U.K. Kidney Cancer Medicine Market Size, 2018-2032
6.4.5 Italy Kidney Cancer Medicine Market Size, 2018-2032
6.4.6 Russia Kidney Cancer Medicine Market Size, 2018-2032
6.4.7 Nordic Countries Kidney Cancer Medicine Market Size, 2018-2032
6.4.8 Benelux Kidney Cancer Medicine Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Kidney Cancer Medicine Revenue, 2018-2032
6.5.2 China Kidney Cancer Medicine Market Size, 2018-2032
6.5.3 Japan Kidney Cancer Medicine Market Size, 2018-2032
6.5.4 South Korea Kidney Cancer Medicine Market Size, 2018-2032
6.5.5 Southeast Asia Kidney Cancer Medicine Market Size, 2018-2032
6.5.6 India Kidney Cancer Medicine Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Kidney Cancer Medicine Revenue, 2018-2032
6.6.2 Brazil Kidney Cancer Medicine Market Size, 2018-2032
6.6.3 Argentina Kidney Cancer Medicine Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Kidney Cancer Medicine Revenue, 2018-2032
6.7.2 Turkey Kidney Cancer Medicine Market Size, 2018-2032
6.7.3 Israel Kidney Cancer Medicine Market Size, 2018-2032
6.7.4 Saudi Arabia Kidney Cancer Medicine Market Size, 2018-2032
6.7.5 UAE Kidney Cancer Medicine Market Size, 2018-2032
7 Kidney Cancer Medicine Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Kidney Cancer Medicine Major Product Offerings
7.1.4 Pfizer Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Company Summary
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb Kidney Cancer Medicine Major Product Offerings
7.2.4 Bristol-Myers Squibb Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.2.5 Bristol-Myers Squibb Key News & Latest Developments
7.3 Roche
7.3.1 Roche Company Summary
7.3.2 Roche Business Overview
7.3.3 Roche Kidney Cancer Medicine Major Product Offerings
7.3.4 Roche Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.3.5 Roche Key News & Latest Developments
7.4 GSK
7.4.1 GSK Company Summary
7.4.2 GSK Business Overview
7.4.3 GSK Kidney Cancer Medicine Major Product Offerings
7.4.4 GSK Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.4.5 GSK Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Kidney Cancer Medicine Major Product Offerings
7.5.4 Novartis Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.5.5 Novartis Key News & Latest Developments
7.6 Bayer
7.6.1 Bayer Company Summary
7.6.2 Bayer Business Overview
7.6.3 Bayer Kidney Cancer Medicine Major Product Offerings
7.6.4 Bayer Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.6.5 Bayer Key News & Latest Developments
7.7 Merck & Co.
7.7.1 Merck & Co. Company Summary
7.7.2 Merck & Co. Business Overview
7.7.3 Merck & Co. Kidney Cancer Medicine Major Product Offerings
7.7.4 Merck & Co. Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.7.5 Merck & Co. Key News & Latest Developments
7.8 Exelixis
7.8.1 Exelixis Company Summary
7.8.2 Exelixis Business Overview
7.8.3 Exelixis Kidney Cancer Medicine Major Product Offerings
7.8.4 Exelixis Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.8.5 Exelixis Key News & Latest Developments
7.9 Takeda
7.9.1 Takeda Company Summary
7.9.2 Takeda Business Overview
7.9.3 Takeda Kidney Cancer Medicine Major Product Offerings
7.9.4 Takeda Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.9.5 Takeda Key News & Latest Developments
7.10 Eisai
7.10.1 Eisai Company Summary
7.10.2 Eisai Business Overview
7.10.3 Eisai Kidney Cancer Medicine Major Product Offerings
7.10.4 Eisai Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.10.5 Eisai Key News & Latest Developments
7.11 CTTQ
7.11.1 CTTQ Company Summary
7.11.2 CTTQ Business Overview
7.11.3 CTTQ Kidney Cancer Medicine Major Product Offerings
7.11.4 CTTQ Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.11.5 CTTQ Key News & Latest Developments
7.12 AVEO Oncology
7.12.1 AVEO Oncology Company Summary
7.12.2 AVEO Oncology Business Overview
7.12.3 AVEO Oncology Kidney Cancer Medicine Major Product Offerings
7.12.4 AVEO Oncology Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.12.5 AVEO Oncology Key News & Latest Developments
7.13 Everest Pharm
7.13.1 Everest Pharm Company Summary
7.13.2 Everest Pharm Business Overview
7.13.3 Everest Pharm Kidney Cancer Medicine Major Product Offerings
7.13.4 Everest Pharm Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.13.5 Everest Pharm Key News & Latest Developments
7.14 Cipla
7.14.1 Cipla Company Summary
7.14.2 Cipla Business Overview
7.14.3 Cipla Kidney Cancer Medicine Major Product Offerings
7.14.4 Cipla Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.14.5 Cipla Key News & Latest Developments
7.15 NATCO
7.15.1 NATCO Company Summary
7.15.2 NATCO Business Overview
7.15.3 NATCO Kidney Cancer Medicine Major Product Offerings
7.15.4 NATCO Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.15.5 NATCO Key News & Latest Developments
7.16 Beacon Pharma
7.16.1 Beacon Pharma Company Summary
7.16.2 Beacon Pharma Business Overview
7.16.3 Beacon Pharma Kidney Cancer Medicine Major Product Offerings
7.16.4 Beacon Pharma Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.16.5 Beacon Pharma Key News & Latest Developments
7.17 SAMARTH
7.17.1 SAMARTH Company Summary
7.17.2 SAMARTH Business Overview
7.17.3 SAMARTH Kidney Cancer Medicine Major Product Offerings
7.17.4 SAMARTH Kidney Cancer Medicine Revenue in Global Market (2018-2023)
7.17.5 SAMARTH Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Kidney Cancer Medicine Market Opportunities & Trends in Global Market
Table 2. Kidney Cancer Medicine Market Drivers in Global Market
Table 3. Kidney Cancer Medicine Market Restraints in Global Market
Table 4. Key Players of Kidney Cancer Medicine in Global Market
Table 5. Top Kidney Cancer Medicine Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Kidney Cancer Medicine Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Kidney Cancer Medicine Revenue Share by Companies, 2018-2023
Table 8. Global Companies Kidney Cancer Medicine Product Type
Table 9. List of Global Tier 1 Kidney Cancer Medicine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Kidney Cancer Medicine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Kidney Cancer Medicine Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Kidney Cancer Medicine Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Kidney Cancer Medicine Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global Kidney Cancer Medicine Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - Kidney Cancer Medicine Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Kidney Cancer Medicine Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global Kidney Cancer Medicine Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global Kidney Cancer Medicine Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Kidney Cancer Medicine Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Kidney Cancer Medicine Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Kidney Cancer Medicine Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Kidney Cancer Medicine Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Kidney Cancer Medicine Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Kidney Cancer Medicine Revenue, (US$, Mn), 2024-2032
Table 30. Pfizer Company Summary
Table 31. Pfizer Kidney Cancer Medicine Product Offerings
Table 32. Pfizer Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. Bristol-Myers Squibb Company Summary
Table 35. Bristol-Myers Squibb Kidney Cancer Medicine Product Offerings
Table 36. Bristol-Myers Squibb Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 37. Bristol-Myers Squibb Key News & Latest Developments
Table 38. Roche Company Summary
Table 39. Roche Kidney Cancer Medicine Product Offerings
Table 40. Roche Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 41. Roche Key News & Latest Developments
Table 42. GSK Company Summary
Table 43. GSK Kidney Cancer Medicine Product Offerings
Table 44. GSK Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 45. GSK Key News & Latest Developments
Table 46. Novartis Company Summary
Table 47. Novartis Kidney Cancer Medicine Product Offerings
Table 48. Novartis Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 49. Novartis Key News & Latest Developments
Table 50. Bayer Company Summary
Table 51. Bayer Kidney Cancer Medicine Product Offerings
Table 52. Bayer Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 53. Bayer Key News & Latest Developments
Table 54. Merck & Co. Company Summary
Table 55. Merck & Co. Kidney Cancer Medicine Product Offerings
Table 56. Merck & Co. Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 57. Merck & Co. Key News & Latest Developments
Table 58. Exelixis Company Summary
Table 59. Exelixis Kidney Cancer Medicine Product Offerings
Table 60. Exelixis Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 61. Exelixis Key News & Latest Developments
Table 62. Takeda Company Summary
Table 63. Takeda Kidney Cancer Medicine Product Offerings
Table 64. Takeda Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 65. Takeda Key News & Latest Developments
Table 66. Eisai Company Summary
Table 67. Eisai Kidney Cancer Medicine Product Offerings
Table 68. Eisai Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 69. Eisai Key News & Latest Developments
Table 70. CTTQ Company Summary
Table 71. CTTQ Kidney Cancer Medicine Product Offerings
Table 72. CTTQ Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 73. CTTQ Key News & Latest Developments
Table 74. AVEO Oncology Company Summary
Table 75. AVEO Oncology Kidney Cancer Medicine Product Offerings
Table 76. AVEO Oncology Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 77. AVEO Oncology Key News & Latest Developments
Table 78. Everest Pharm Company Summary
Table 79. Everest Pharm Kidney Cancer Medicine Product Offerings
Table 80. Everest Pharm Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 81. Everest Pharm Key News & Latest Developments
Table 82. Cipla Company Summary
Table 83. Cipla Kidney Cancer Medicine Product Offerings
Table 84. Cipla Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 85. Cipla Key News & Latest Developments
Table 86. NATCO Company Summary
Table 87. NATCO Kidney Cancer Medicine Product Offerings
Table 88. NATCO Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 89. NATCO Key News & Latest Developments
Table 90. Beacon Pharma Company Summary
Table 91. Beacon Pharma Kidney Cancer Medicine Product Offerings
Table 92. Beacon Pharma Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 93. Beacon Pharma Key News & Latest Developments
Table 94. SAMARTH Company Summary
Table 95. SAMARTH Kidney Cancer Medicine Product Offerings
Table 96. SAMARTH Kidney Cancer Medicine Revenue (US$, Mn) & (2018-2023)
Table 97. SAMARTH Key News & Latest Developments
List of Figures
Figure 1. Kidney Cancer Medicine Segment by Type in 2022
Figure 2. Kidney Cancer Medicine Segment by Application in 2022
Figure 3. Global Kidney Cancer Medicine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Kidney Cancer Medicine Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Kidney Cancer Medicine Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Kidney Cancer Medicine Revenue in 2022
Figure 8. By Type - Global Kidney Cancer Medicine Revenue Market Share, 2018-2032
Figure 9. By Application - Global Kidney Cancer Medicine Revenue Market Share, 2018-2032
Figure 10. By Type - Global Kidney Cancer Medicine Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global Kidney Cancer Medicine Revenue Market Share, 2018-2032
Figure 12. By Application - Global Kidney Cancer Medicine Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global Kidney Cancer Medicine Revenue Market Share, 2018-2032
Figure 14. By Region - Global Kidney Cancer Medicine Revenue Market Share, 2018-2032
Figure 15. By Country - North America Kidney Cancer Medicine Revenue Market Share, 2018-2032
Figure 16. US Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 17. Canada Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe Kidney Cancer Medicine Revenue Market Share, 2018-2032
Figure 20. Germany Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 21. France Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 23. Italy Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 24. Russia Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia Kidney Cancer Medicine Revenue Market Share, 2018-2032
Figure 28. China Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 29. Japan Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 32. India Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America Kidney Cancer Medicine Revenue Market Share, 2018-2032
Figure 34. Brazil Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa Kidney Cancer Medicine Revenue Market Share, 2018-2032
Figure 37. Turkey Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 38. Israel Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 40. UAE Kidney Cancer Medicine Revenue, (US$, Mn), 2018-2032
Figure 41. Pfizer Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Bristol-Myers Squibb Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Roche Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. GSK Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Novartis Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bayer Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Merck & Co. Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Exelixis Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Takeda Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Eisai Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. CTTQ Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. AVEO Oncology Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Everest Pharm Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Cipla Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. NATCO Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Beacon Pharma Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. SAMARTH Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
